Gender- and sex-based disparities in response to immune-checkpoint inhibitors (ICI) has been reported in a variety of tumor types. Women have different anatomy with recurrent urinary tract infections, a different sex hormonal profile, and intrinsic differences in local and systemic immune systems and urobiome composition. Existing literature data in a pan-cancer context reveal contradictory results, and real-world evidence in urothelial carcinoma (UC) is lacking. This was a real-world, multicenter, international, observational study to determine the sex effects on the clinical outcomes in metastatic urothelial carcinoma (mUC) patients progressing or recurring after platinum-based therapy and treated with pembrolizumab as a part of routine clinical care. A total of 1039 patients, treated from January 1st, 2016 to December 31st, 2023 in 68 cancer centers were included. Our data showed that women with metastatic urothelial carcinoma treated with pembrolizumab had shorter OS than men, with a 13% advantage in the 5-year OS rate for male patients. A deeper understanding of these results may inform sex-stratification in future prospective clinical trials and help develop strategies to reduce the magnitude of the sex disparities observed in urothelial cancer outcomes.
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab / Incorvaia, Lorena; Scagliarini, Sarah; Marques Monteiro, Fernando Sabino; Takeshita, Hideki; Tapia, Jose Carlos; Gandur Quiroga, María Natalia; Lam, Elaine; Tural, Deniz; Popovic, Lazar; Campos-Gomez, Saul; Zucali, Paolo Andrea; Mota, Augusto; Ortega, Cinzia; Sade, Juan Pablo; Rizzo, Mimma; Fiala, Ondřej; Vau, Nuno; Giannatempo, Patrizia; Abahssain, Halima; Galosi, Andrea Benedetto; Badalamenti, Giuseppe; Kopecky, Jindrich; Bamias, Aristotelis; Landmesser, Johannes; Ansari, Jawaher; Calabrò, Fabio; Massari, Francesco; Buti, Sebastiano; Bellmunt, Joaquim; Santoni, Matteo. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 15:1(2025), p. 8815. [10.1038/s41598-025-93094-2]
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab
Buti, SebastianoConceptualization
;
2025-01-01
Abstract
Gender- and sex-based disparities in response to immune-checkpoint inhibitors (ICI) has been reported in a variety of tumor types. Women have different anatomy with recurrent urinary tract infections, a different sex hormonal profile, and intrinsic differences in local and systemic immune systems and urobiome composition. Existing literature data in a pan-cancer context reveal contradictory results, and real-world evidence in urothelial carcinoma (UC) is lacking. This was a real-world, multicenter, international, observational study to determine the sex effects on the clinical outcomes in metastatic urothelial carcinoma (mUC) patients progressing or recurring after platinum-based therapy and treated with pembrolizumab as a part of routine clinical care. A total of 1039 patients, treated from January 1st, 2016 to December 31st, 2023 in 68 cancer centers were included. Our data showed that women with metastatic urothelial carcinoma treated with pembrolizumab had shorter OS than men, with a 13% advantage in the 5-year OS rate for male patients. A deeper understanding of these results may inform sex-stratification in future prospective clinical trials and help develop strategies to reduce the magnitude of the sex disparities observed in urothelial cancer outcomes.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
